Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers

Nicotine and other constituents of tobacco smoke elevate dopamine (DA) and serotonin (5‐HT) levels in brain and may cause homeostatic adaptations in DA and 5‐HT transporters. Since sex steroids alter DA and 5‐HT transporter expression, the effects of smoking on DA and 5‐HT transporter availability may differ between sexes. In the present study, DA and 5‐HT transporter availabilities were quantitated using single photon emission computed tomography (SPECT) imaging approximately 22 h after bolus administration of [123I]β‐CIT, an analog of cocaine which labels DA and 5‐HT transporters. Forty‐two subjects including 21 pairs of age‐, race‐, and gender‐matched healthy smokers and nonsmokers (12 female and 9 male pairs) were imaged. Regional uptake was assessed by the outcome measures, V3″, which is the ratio of specific (i.e., ROI‐cerebellar activity) to nondisplaceable (cerebellar) activity, and V3, the ratio of specific to free plasma parent. Overall, striatal and diencephalic [123I]β‐CIT uptake was not altered by smoking, whereas brainstem [123I]β‐CIT uptake was modestly higher (10%) in smokers vs. nonsmokers. When subgrouped by sex, regardless of smoking status, [123I]β‐CIT uptake was higher in the striatum (10%), diencephalon (15%), and brainstem (15%) in females vs. males. The sex*smoking interaction was not significant in the striatum, diencephalon, or brainstem, despite the observation of 20% higher brainstem [123I]β‐CIT uptake in male smokers vs. nonsmokers and less than a 5% difference between female smokers and nonsmokers. The results demonstrate higher DA and 5‐HT transporter availability in females vs. males and no overall effect of smoking with the exception of a modest elevation in brainstem 5‐HT transporters in male smokers. Although these findings are preliminary and need validation with a more selective 5‐HT transporter radiotracer, the results suggest that brainstem 5‐HT transporters may be regulated by smoking in a sex‐specific manner. Synapse 41:275–284, 2001. © 2001 Wiley‐Liss, Inc.

[1]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[2]  T. Hökfelt,et al.  On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons , 1979, Pharmacology Biochemistry and Behavior.

[3]  D. Balfour Influence of nicotine on the release of monoamines in the brain. , 1989, Progress in brain research.

[4]  N. Volkow,et al.  Inhibition of monoamine oxidase B in the brains of smokers , 1996, Nature.

[5]  T. Di Paolo,et al.  Sex and estrous cycle variations of rat striatal dopamine uptake sites. , 1993, Neuroendocrinology.

[6]  G. Goodwin,et al.  Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.

[7]  L. Werling,et al.  Nicotinic receptor‐mediated regulation of dopamine transporter activity in rat prefrontal cortex , 2000, Synapse.

[8]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  H. Friedman,et al.  The importance of measuring cotinine levels to identify smokers in clinical trials , 1994, Clinical pharmacology and therapeutics.

[10]  S. Hall,et al.  Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. , 1996, Journal of consulting and clinical psychology.

[11]  F I Carroll,et al.  High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.

[12]  C. Pomerleau,et al.  Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. , 1994, Addictive behaviors.

[13]  N. Volkow,et al.  Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. , 1998, Journal of addictive diseases.

[14]  J. Aronstein,et al.  Environmental conditions of residential electrical connections , 1998, Electrical Contacts - 1998. Proceedings of the Forty-Fourth IEEE Holm Conference on Electrical Contacts (Cat. No.98CB36238).

[15]  L. Reneman,et al.  Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers , 2000, European Journal of Nuclear Medicine.

[16]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[17]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[18]  Alexander Neumeister,et al.  [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder , 2000, Biological Psychiatry.

[19]  Carl J. Huberty,et al.  Multivariate Analysis of Variance and Covariance , 2000 .

[20]  G. Chiara,et al.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.

[21]  B. Winblad,et al.  The regional distribution of dopamine and serotonin uptake and transmitter concentrations in the human brain , 1987, Neurochemistry International.

[22]  E Méndez-Alvarez,et al.  Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. , 1997, Life Science.

[23]  T. Westfall,et al.  Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. , 1983, General pharmacology.

[24]  T. Arinami,et al.  A Synergistic Effect of Serotonin Transporter Gene Polymorphism and Smoking in Association with CHD , 1999, Thrombosis and Haemostasis.

[25]  J. Hietala,et al.  High levels of dopamine activity in the basal ganglia of cigarette smokers. , 2000, The American journal of psychiatry.

[26]  R. Salín-Pascual,et al.  Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. , 1996, The Journal of clinical psychiatry.

[27]  M. Bleecker,et al.  The factor structure of the Profile of Mood States (POMS) and its relationship to occupational lead exposure. , 1999, Journal of occupational and environmental medicine.

[28]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[29]  M. Kuhar,et al.  [125I]RTI-55: a potent ligand for dopamine transporters. , 1991, European journal of pharmacology.

[30]  L. Dwoskin,et al.  Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. , 1997, Biochemical pharmacology.

[31]  I. Podreka,et al.  Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .

[32]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[33]  M. Morissette,et al.  Effect of Chronic Estradiol and Progesterone Treatments of Ovariectomized Rats on Brain Dopamine Uptake Sites , 1993, Journal of neurochemistry.

[34]  Robert B. Innis,et al.  Evaluation of the monoamine uptake site ligand [131I]methyl 3β-(4-Iodophenyl)-tropane-2β-carboxylate ([123I]β-CIT) in non-human primates: Pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI , 1993 .

[35]  G. Cassano,et al.  Effect of aging and sex on the [3H]-paroxetine binding to human platelets. , 1998, Journal of affective disorders.

[36]  Ronald C. Kessler,et al.  Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. , 1994 .

[37]  G. Fink,et al.  Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. , 1997, Brain research. Molecular brain research.

[38]  M Laruelle,et al.  Regional distribution of serotonergic pre‐ and postsynaptic markers in human brain , 1989, Acta psychiatrica Scandinavica. Supplementum.

[39]  D. Charney,et al.  Age-Related Decline in Striatal Dopamine Transporter Binding with Iodine-123-β-CITSPECT , 1995 .

[40]  H. Schievelbein,et al.  MECHANISM OF THE RELEASE OF AMINES BY NICOTINE , 1967 .

[41]  M. Benwell,et al.  The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain. , 1982, European journal of pharmacology.

[42]  E F Domino,et al.  Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers , 2000, Synapse.

[43]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[44]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[45]  I G Zubal,et al.  Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  S. Tiffany,et al.  The development and initial validation of a questionnaire on smoking urges. , 1991, British journal of addiction.

[47]  G. Fink,et al.  Serotonin transporter (SERT) mRNA and binding site densities in male rat brain affected by sex steroids. , 1999, Brain research. Molecular brain research.

[48]  R. Rivest,et al.  Brain dopamine transporter: gender differences and effect of chronic haloperidol , 1995, Brain Research.

[49]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[50]  S M Dursun,et al.  Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. , 1999, Medical hypotheses.

[51]  R. Kessler,et al.  Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. , 1997, Drug and alcohol dependence.

[52]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[53]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[54]  R. Wurtman,et al.  Effects of systemic nicotine on serotonin release in rat brain , 1993, Brain Research.

[55]  M. Picciotto Common aspects of the action of nicotine and other drugs of abuse. , 1998, Drug and alcohol dependence.

[56]  J. Court,et al.  Distribution of nicotinic subtypes in human brain. , 1995, Alzheimer disease and associated disorders.

[57]  A. Neale,et al.  Neurobehavioral and health-related deficits in solvent-exposed painters. , 1996, American journal of industrial medicine.

[58]  E. Perry,et al.  Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.

[59]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT , 2000, Neurobiology of Aging.

[60]  J. Rausch,et al.  Effect of nicotine on human blood platelet serotonin uptake and efflux , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[61]  M. Jarvis,et al.  Plasma cotinine: stability in smokers and validation of self-reported smoke exposure in nonsmokers. , 1994, Environmental research.

[62]  D. Mash,et al.  Visualizing Dopamine and Serotonin Transporters in the Human Brain with the Potent Cocaine Analogue [125I]RTI‐55: In Vitro Binding and Autoradiographic Characterization , 1994, Journal of neurochemistry.